Condition

Prostatic Intraepithelial Neoplasia

ClinicalTrials.gov condition label

Clinical trials6

Recruiting0

Common interventions10

Lead sponsors shown5

Clinical trials

6 shown

Annexin A3 (ANXA3) as Protein-Based Marker for Non-Invasive Molecular Diagnostics of Prostate CarcinomaNCT00400894 · 2005-09-01

Broccoli, Peas and PINNCT00535977 · 2005-04-01

Prostate Cancer Prevention Study for Men With High Grade PIN (Prostatic Intraepithelial Neoplasia)NCT00106691 · 2005-01-01

Finasteride and Flutamide in Pre-surgical Trial in Prostate Cancer.NCT06601205 · 2004-01-01

A Pilot Study of Lycopene Supplementation in Prostatic Intraepithelial NeoplasiaNCT00178113 · 2003-07-01

A Chemoprevention Study of an Investigational Drug in Men With High Grade Prostate Intraepithelial Neoplasia (PIN)NCT00028353 · 2001-04-01

Common interventions

- Certagen (multivitamins with minerals)DRUG1 - Lyc-O-Mato (dietary supplement, 30 mg lycopene/day)DRUG1 BroccoliDIETARY_SUPPLEMENT1 FinasterideDRUG1 FlutamideDRUG1 GTX-006 (Acapodene)DRUG1 PeasDIETARY_SUPPLEMENT1 PlaceboDRUG1 PlaceboOTHER1 Toremifene 20 mgDRUG1

Leading sponsors

GTx2 Ente Ospedaliero Ospedali Galliera1 ProteoSys AG1 Quadram Institute Bioscience1 University of Pittsburgh1

Trial status mix

COMPLETED5

UNKNOWN1

Phase mix

PHASE22

PHASE32

NA1

PHASE11

How to interpret this record

CureCurrent links normalized diseases, medicines, registry study labels, sponsors and research sites. A link is not the same as a finding of clinical effectiveness. Our research guides explain how to compare studies, decode RxNorm identities, and avoid over-interpreting site and trial counts. See the published database coverage for mapping completeness.

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.